Bridgeway Capital Management, LLC Rigel Pharmaceuticals Inc Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $84,000 - $117,750	-75,000 Reduced 11.19%	595,400 $881,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $54,864 - $118,872	76,200 Added 12.82%	670,400 $972,000
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $234,544 - $304,688	219,200 Added 58.45%	594,200 $641,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $128,800 - $209,300	115,000 Added 44.23%	375,000 $483,000
Q1 2023 May 15, 2023	SELL	$1.25 - $2.0 $81,250 - $130,000	-65,000 Reduced 20.0%	260,000 $343,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $357,500 - $3.97 Million	325,000 New	325,000 $384,000
Q4 2017 Feb 14, 2018	SELL	$3.23 - $4.3 $509,694 - $678,540	-157,800 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $344,004 - $405,546	157,800	157,800 $401,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.